Featured Research

from universities, journals, and other organizations

Researchers Report Emergence Of Antibiotic Resistance During Vancomycin Therapy

Date:
February 19, 1999
Source:
The Rockefeller University
Summary:
A team of researchers led by The Rockefeller University's Alexander Tomasz, Ph.D., have described the case of a 79-year-old patient whose death in a New York metropolitan area hospital last March was associated with a bloodstream infection caused by a multidrug-resistant strain of Staphylococcus aureus. The report, published in the Feb. 18 issue of the New England Journal of Medicine (NEJM), showed that the bacteria, which had decreased susceptibility to vancomycin, could be treated effectively with a combination of antibiotics.

Antibiotic Combination Shown To Be Effective against Resistant Bug

A team of researchers led by The Rockefeller University's Alexander Tomasz, Ph.D., have described the case of a 79-year-old patient whose death in a New York metropolitan area hospital last March was associated with a bloodstream infection caused by a multidrug-resistant strain of Staphylococcus aureus. The report, published in the Feb. 18 issue of the New England Journal of Medicine (NEJM), showed that the bacteria, which had decreased susceptibility to vancomycin, could be treated effectively with a combination of antibiotics.

"We think that this is the first demonstration that selection for strains with increased resistance to vancomycin can occur during therapy," says Tomasz, senior author of the paper and professor and head of the Laboratory of Microbiology.

The case described in the NEJM article was the fourth in the world associated with infections caused by multiresistant strains of Staphylococcus aureus (MRSA) that also show partial resistance to vancomycin, a drug often described as the "last resort" antibiotic against these dangerous pathogens that cause many hospital-acquired infections in the United States and elsewhere.

"The emergence of vancomycin-resistant Staphylococcus aureus strains emphasizes the importance of appropriate vancomycin dosing to assure complete eradication of the bacteria," says Richard B. Roberts, M.D., a co-author of the report and an adjunct professor at Rockefeller and professor of medicine at New York Hospital-Cornell Medical Center.

A hopeful finding reported by the Rockefeller team is that a combination of two commonly used antibiotics, oxacillin and vancomycin, produced a synergistic effect and killed the vancomycin-resistant MRSA very efficiently in the test tube.

"If these results can be translated into the clinical setting, they suggest that a combination of vancomycin and oxacillin may be an effective therapeutic regimen against vancomycin-resistant staphylococci," says Tomasz.

Antibiotic resistance is a growing public health problem. In a study published in the July 1998 issue of the Journal of Infectious Diseases, the Rockefeller group in collaboration with colleagues at the Public Health Research Institute used molecular fingerprinting techniques to demonstrate the extensive spread of a single multidrug-resistant Staphylococcus aureus strain dubbed "the New York clone of MRSA" in 12 hospitals in the New York metropolitan area.

Tomasz and Roberts's co-authors are first author Krzysztof Sieradzki, Ph.D., a postdoctoral fellow at Rockefeller, and Stuart W. Haber, M.D., of United Hospital Medical Center in Port Chester, N.Y.

The research described in the NEJM paper was supported in part by The Glickenhaus Foundation, The Bodman and Achelis Foundations, and the Cary L. Guy Foundation.

Rockefeller began in 1901 as The Rockefeller Institute for Medical Research, the first U.S. biomedical research center. Rockefeller faculty members have made significant achievements, including the discovery that DNA is the carrier of genetic information and the launching of the scientific field of modern cell biology. The university has ties to 19 Nobel laureates. Thirty-three faculty members are elected members of the U.S. National Academy of Sciences, including President Arnold J. Levine, Ph.D.


Story Source:

The above story is based on materials provided by The Rockefeller University. Note: Materials may be edited for content and length.


Cite This Page:

The Rockefeller University. "Researchers Report Emergence Of Antibiotic Resistance During Vancomycin Therapy." ScienceDaily. ScienceDaily, 19 February 1999. <www.sciencedaily.com/releases/1999/02/990219080817.htm>.
The Rockefeller University. (1999, February 19). Researchers Report Emergence Of Antibiotic Resistance During Vancomycin Therapy. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/1999/02/990219080817.htm
The Rockefeller University. "Researchers Report Emergence Of Antibiotic Resistance During Vancomycin Therapy." ScienceDaily. www.sciencedaily.com/releases/1999/02/990219080817.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins